Intravesical Toll-like receptor 7 agonist R-837: Optimization of its formulation in an orthotopic mouse model of bladder cancer

International Journal of Urology

Volumn 17, Issue 5, 2010, Pages 483-490

  Hayashi, Tomoko ^a   Crain, Brian ^a   Corr, Maripat ^b   Chan, Michael ^a   Cottam, Howard B ^a   Maj, Roberto ^c   Barberis, Alcide ^c   Leoni, Lorenzo ^c   Carson, Dennis A ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Telormedix SA   (Switzerland)

Author keywords

Bladder cancer; Cyclodextrin; Formulation; Poloxamer; Toll like receptor 7 agonist

Indexed keywords

IMIQUIMOD; KERATINOCYTE DERIVED CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; GENE INDUCTION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AMINOQUINOLINES; ANIMALS; BETA-CYCLODEXTRINS; CHEMISTRY, PHARMACEUTICAL; CYSTITIS; CYTOKINES; DISEASE MODELS, ANIMAL; EXCIPIENTS; FEMALE; LACTIC ACID; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; POLYETHYLENES; POLYPROPYLENES; TOLL-LIKE RECEPTOR 7; URINARY BLADDER NEOPLASMS;

EID: 77951286282     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02503.x     Document Type: Article

References (29)

1. Schenk-Braat EA, Bangma CH. Immunotherapy for superficial bladder cancer. Cancer Immunol. Immunother. 2005 54 : 414 423.
2. Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stockle M, Sternberg C. Guidelines on bladder cancer. Eur. Urol. 2002 41 : 105 112.
3. De Boer EC, Rooijakkers SJ, Schamhart DH, Kurth KH. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response. J. Urol. 2003 170 : 2004 2008.
4. Suttmann H, Riemensberger J, Bentien G et al. Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res. 2006 66 : 8250 8257.
5. Simons MP, O'Donnell MA, Griffith TS. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol. Oncol. 2008 26 : 341 345.
6. Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J. Urol. 2003 170 : 964 969.
7. Purdon CH, Azzi CG, Zhang J, Smith EW, Maibach HI. Penetration enhancement of transdermal delivery - current permutations and limitations. Crit. Rev. Ther. Drug Carrier Syst. 2004 21 : 97 132.
8. Chang YC, Madkan V, Cook-Norris R, Sra K, Tyring S. Current and potential uses of imiquimod. South. Med. J. 2005 98 : 914 920.
9. Wagstaff AJ, Perry CM. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs 2007 67 : 2187 2210.
10. Chan M, Hayashi T, Kuy CS et al. Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates. Bioconjug. Chem. 2009 20 : 1194 1200.
11. Barnetson RS, Satchell A, Zhuang L, Slade HB, Halliday GM. Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells. Clin. Exp. Dermatol. 2004 29 : 639 643.
12. Smith EB, Schwartz M, Kawamoto H et al. Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J. Urol. 2007 177 : 2347 2351.
13. Hegele A, Dalpke A, Heeg K et al. Immunostimulatory CpG oligonucleotides reduce tumor burden after intravesical administration in an orthotopic murine bladder cancer model. Tumour Biol. 2005 26 : 274 280.
14. Olbert PJ, Schrader AJ, Simon C et al. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall. Anticancer Res. 2009 29 : 2067 2076.
15. Hegele A, Dalpke A, Barth P et al. Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model. Anticancer Res. 2004 24 : 2225 2230.
16. Chollet JL, Jozwiakowski MJ, Phares KR et al. Development of a topically active imiquimod formulation. Pharm. Dev. Technol. 1999 4 : 35 43.
17. Hayashi T, Cottam HB, Chan M et al. Mast cell-dependent anorexia and hypothermia induced by mucosal activation of Toll-like receptor 7. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008 295 : R123 32.
18. Liu H, Schwartz MJ, Hwang DH, Scherr DS. Tumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma. BJU Int. 2008 101 : 894 901.
19. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999 353 : 1689 1694.
20. Games J. Nursing implications in the management of superficial bladder cancer. Semin. Urol. Oncol. 1996 14 : 36 40.
21. Mangsbo SM, Ninalga C, Essand M, Loskog A, Totterman TH. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. J. Immunother. 2008 31 : 34 42.
22. Atkins H, Davies BR, Kirby JA, Kelly JD. Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy. Br. J. Cancer 2003 89 : 2312 2319.
23. Akazawa T, Masuda H, Saeki Y et al. Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Cancer Res. 2004 64 : 757 764.
24. Anderson BC, Pandit NK, Mallapragada SK. Understanding drug release from poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) gels. J. Control. Release 2001 70 : 157 167.
25. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 2007 59 : 645 666.
26. Bilensoy E, Rouf MA, Vural I, Sen M, Hincal AA. Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole:beta- cyclodextrin complex. AAPS PharmSciTech. 2006 7 E38.
27. Chang JY, Oh YK, Kong HS et al. Prolonged antifungal effects of clotrimazole-containing mucoadhesive thermosensitive gels on vaginitis. J. Control. Release 2002 82 : 39 50.
28. Saban MR, Simpson C, Davis C et al. Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG). BMC Immunol. 2007 8 : 6.
29. Luo Y, Chen X, O'Donnell MA. Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. Cytokine 2003 21 : 17 26.